Erleada works by blocking the effect of androgens, a type of hormone, on the tumor. These androgens, such as testosterone, can promote tumor growth. The safety and efficacy of Erleada was based on a randomized clinical trial of 1,207 patients with non-metastatic, castration-resistant prostate cancer.

How long do patients take Erleada?

Erleada (apalutamide) is usually taken until cancer progresses past a certain point or you start to have unacceptable side effects. In the SPARTAN clinical trial (NCT01946204) using apalutamide for men with castration-resistant metastasis-free prostate cancer, some patients were still using apalutamide at 36 months.

Does Erleada lower PSA?

Erleada achieved an 86 percent reduction in PSA at 12 months in the majority of patients, shows post-hoc analysis of Phase III study.